We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Darren S. Brown
Darren S. Brown
Products
PRODUCTS
Mylan Laboratories Ltd.
Darren S. Brown
and
Nayan J. Patel
Price:
$117.00
View
SICOR Societa Italiana Corticosteroidi S.R.I
Darren S. Brown
Price:
$117.00
View
Laboratorio Reig Jofre, S.A.
Darren S. Brown
and
Santos E. Camara
Price:
$117.00
View
Gordon Laboratories, Inc.
Darren S. Brown
Price:
$117.00
View
Zaklady Farmaceutyczne Pophanna S.A.
Darren S. Brown
Price:
$117.00
View
Phrumacosmos NS
Darren S. Brown
Price:
$117.00
View
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Darren S. Brown
,
Djamila Harouaka
, and
Rose Xu
Price:
$117.00
View
Technichem Corp.
Darren S. Brown
Price:
$117.00
View
IBI - Istituto Biochimico Italiano Giovanni Lorenzini S.p.A.
Darren S. Brown
Price:
$117.00
View
Strides Shasun, Ltd.
Tamil Arasu
and
Darren S. Brown
Price:
$117.00
View
View All Products by Darren S. Brown
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More